These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31690606)

  • 1. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
    Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
    BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
    Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
    Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
    Naddell S; Manuel M; Cavill R; White P; Sieradzan K
    Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.
    Schubert-Bast S; Willems LM; Kurlemann G; Knake S; Müller-Schlüter K; Rosenow F; Strzelczyk A
    Epilepsy Behav; 2018 Dec; 89():89-93. PubMed ID: 30390435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
    Stephen L; Brodie MJ
    Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
    Steinhoff BJ; Bacher M; Bucurenciu I; Hillenbrand B; Intravooth T; Kornmeier R; Kurth C; Stockinger J; Staack AM
    Seizure; 2017 May; 48():11-14. PubMed ID: 28364655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
    Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
    Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Irelli EC; Chiesa V; Dainese F; De Maria G; Didato G; Gennaro GD; Falcicchio G; Fanella M; Ferlazzo E; Gangitano M; La Neve A; Mecarelli O; Montalenti E; Morano A; Piazza F; Pizzanelli C; Pulitano P; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    Seizure; 2022 Apr; 97():37-42. PubMed ID: 35320736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.